Holen Sie sich die Stockscreener-App
5.76
0.88%
0.05
Handel nachbörslich:
5.76
Schlusskurs vom Vortag:
$5.71
Offen:
$5.8
24-Stunden-Volumen:
136.20K
Relative Volume:
0.74
Marktkapitalisierung:
$35.64M
Einnahmen:
$2.19M
Nettoeinkommen (Verlust:
$-24.19M
KGV:
-0.6696
EPS:
-8.6017
Netto-Cashflow:
$-82.94M
1W Leistung:
+0.88%
1M Leistung:
-11.52%
6M Leistung:
-37.46%
1J Leistung:
+1.59%
1-Tages-Spanne:
$5.7101
$6.11
1-Wochen-Bereich:
$5.16
$6.11
52-Wochen-Spanne:
$5.12
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Firmenname
Aligos Therapeutics Inc
Sektor
Branche
Telefon
(800) 466-6059
Adresse
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
5.76 | 35.33M | 2.19M | -24.19M | -82.94M | -8.6017 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-19 | Fortgesetzt | Jefferies | Buy |
| 2025-08-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-08-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-01-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-01-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-09 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Eingeleitet | JP Morgan | Overweight |
| 2020-11-10 | Eingeleitet | Jefferies | Buy |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Aligos Therapeutics Inc Aktie (ALGS) Neueste Nachrichten
Cantor Fitzgerald Initiates Aligos Therapeutics(ALGS.US) With Buy Rating, Announces Target Price $20 - Moomoo
ALGS Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov - GuruFocus
ALGS News | ALIGOS THERAPEUTICS INC (NASDAQ:ALGS) - ChartMill
Lawrence M. Blatt discloses 5.1% stake in Aligos Therapeutics (ALGS) - Stock Titan
Aligos (ALGS) Delivers Q1 2026 Beat — EPS $-2.21 vs $-2.27 ExpectedSocial Trade Signals - Newser
Woodline Partners reports 4.4% stake in Aligos Therapeutics (NASDAQ: ALGS) - Stock Titan
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at EASL Congress 2026 - Quiver Quantitative
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 - Weekly Voice
Liver disease drug data: Aligos secures 10 EASL 2026 slots - Stock Titan
TradingKey - TradingKey
What you need to know before buying Aligos (ALGS) (Investor Concern) 2026-05-08Crowd Consensus Signals - newser.com
The operating leverage hidden in Aligos (ALGS) results | Q1 2026: EPS Exceeds ExpectationsTarget Revision - Newser
Aligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat - ChartMill
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - Investing News Network
China HBV license adds cash as Aligos (NASDAQ: ALGS) faces going‑concern risk - Stock Titan
Aligos lands FDA Fast Track and a $25M China deal for HBV drug - Stock Titan
Earnings Preview: ALGS to Report Financial Results Post-market on May 07 - Moomoo
How Aligos Therapeutics Inc. (ALGS) Affects Rotational Strategy Timing - Stock Traders Daily
Aligos Therapeutics Inc expected to post a loss of $2.22 a shareEarnings Preview - TradingView
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 - Investing News Network
Biotech Aligos will post first-quarter results after markets close May 7 - Stock Titan
[ARS] Aligos Therapeutics, Inc. SEC Filing - Stock Titan
Aligos Therapeutics says China pact puts HBV drug in focus amid trial updates - MSN
Aligos Therapeutics (Nasdaq: ALGS) details ESPP, auditor and pay votes - Stock Titan
Aligos’ licensing deal in China broadens trial scope, secures immediate $25m - MLex
Is Aligos (ALGS) overbought or oversold? (Drifts Higher) 2026-04-27Retail Flow - Newser
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
This micro cap biotech stock is tracking its biggest intraday gains in 11 months – here’s why a China deal has retail buzzing - MSN
(ALGS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Aligos Therapeutics (ALGS) Gets a Buy from H.C. Wainwright - The Globe and Mail
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
New Aligos hires get stock options for 10,700 shares under Nasdaq rule - Stock Titan
Aligos Therapeutics jumps on China licensing agreement - MSN
Deal Watch: First Quarter Posted High Volume, Dollar Value In Alliance Deals - Citeline News & Insights
Aligos (ALGS) Stock: Why Margin Improvement (Institutional Demand) 2026-04-22Short Term Trading - Cổng thông tin điện tử tỉnh Tây Ninh
Aligos Therapeutics Licenses Hepatitis B Drug Rights to Amoytop - TipRanks
Aligos Therapeutics (NASDAQ: ALGS) signs Hep B deal with up to $420M milestones - Stock Titan
Aligos (ALGS) Stock Volume Confirmation (Wavering) 2026-04-20Earnings Season - Cổng thông tin điện tử tỉnh Lào Cai
10 Health Care Stocks Moving In Friday's Intraday Session - Sahm
H.C. Wainwright reiterates Aligos stock rating on China deal - Investing.com UK
Aligos strikes license deal with Amoytop for HBV therapy development - The Pharma Letter
This drugmaker was about to run out of cash, but a Chinese partner came to the rescue - The Business Journals
H.C. Wainwright reiterates Aligos stock rating on China deal By Investing.com - Investing.com Canada
Finanzdaten der Aligos Therapeutics Inc-Aktie (ALGS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):